• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.

作者信息

Wan Chao-Ling, Zou Jing-Ying, Qiao Man, Yin Jia, Shen Xiang-Dong, Qiu Qiao-Cheng, Liu Song-Bai, Xue Sheng-Li

机构信息

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

出版信息

Leuk Lymphoma. 2021 Dec;62(13):3300-3303. doi: 10.1080/10428194.2021.1957876. Epub 2021 Jul 29.

DOI:10.1080/10428194.2021.1957876
PMID:34323656
Abstract
摘要

相似文献

1
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.维奈托克联合阿扎胞苷作为复发或难治性T细胞急性淋巴细胞白血病的一种有效且安全的挽救方案：病例系列
Leuk Lymphoma. 2021 Dec;62(13):3300-3303. doi: 10.1080/10428194.2021.1957876. Epub 2021 Jul 29.
2
Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.维奈托克联合地西他滨及HAAG方案：复发/难治性T细胞急性淋巴细胞白血病的一种新型挽救策略
Ann Hematol. 2022 Nov;101(11):2525-2528. doi: 10.1007/s00277-022-04912-w. Epub 2022 Sep 5.
3
Hypomethylating agents and venetoclax in acute myeloid leukemia.急性髓系白血病中的去甲基化药物与维奈克拉
Clin Adv Hematol Oncol. 2021 Feb;19(2):82-83.
4
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
5
Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.维奈克拉联合HAG方案挽救了复发/难治性早期T细胞前体急性淋巴细胞白血病。
Ann Hematol. 2020 Feb;99(2):395-397. doi: 10.1007/s00277-019-03902-9. Epub 2019 Dec 26.
6
Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.维奈托克与地西他滨治疗儿童难治性T细胞淋巴母细胞淋巴瘤
J Pediatr Hematol Oncol. 2021 Oct 1;43(7):e991-e996. doi: 10.1097/MPH.0000000000002050.
7
[Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia].维奈托克联合多药化疗治疗15例复发或难治性早期T细胞前体急性淋巴细胞白血病的临床疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2023 Aug 14;44(8):649-653. doi: 10.3760/cma.j.issn.0253-2727.2023.08.006.
8
Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy.一线维奈托克联合低甲基化药物治疗失败后急性髓系白血病患者的预后
Haematologica. 2023 Nov 1;108(11):3170-3174. doi: 10.3324/haematol.2022.282677.
9
Venetoclax with decitabine or azacitidine for AML.维奈托克联合地西他滨或阿扎胞苷治疗急性髓系白血病
Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1.
10
Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.维奈托克联合化疗用于复发/难治性早期T细胞前体急性淋巴细胞白血病
Leuk Lymphoma. 2021 Sep;62(9):2292-2294. doi: 10.1080/10428194.2021.1897807. Epub 2021 Mar 10.

引用本文的文献

1
Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review.维奈托克与CHG方案联合治疗难治性/复发性T淋巴细胞淋巴瘤/急性淋巴细胞白血病：病例系列及文献综述
Discov Oncol. 2025 Jul 1;16(1):1202. doi: 10.1007/s12672-025-03055-4.
2
Daratumumab, Venetoclax, and Azacitidine in Combination with the HAA Regimen as Consolidation Chemotherapy for T-Cell Acute Lymphoblastic Leukemia with High CD38 Expression.达雷妥尤单抗、维奈克拉和阿扎胞苷联合HAA方案作为巩固化疗用于治疗高表达CD38的T细胞急性淋巴细胞白血病
Turk J Haematol. 2025 Aug 29;42(3):232-234. doi: 10.4274/tjh.galenos.2025.2025.0019. Epub 2025 May 6.
3
Promising Drugs Targeting Specific Mechanisms of Deregulation in T Cell Lineage Acute Lymphoblastic Leukemia.
针对T细胞系急性淋巴细胞白血病特定失调机制的有前景的药物
Oncol Ther. 2025 Apr 18. doi: 10.1007/s40487-025-00339-1.
4
Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.基于维奈托克的低强度化疗用于复发/难治性T细胞急性淋巴细胞白血病的挽救治疗
Clin Exp Med. 2025 Apr 2;25(1):104. doi: 10.1007/s10238-025-01638-7.
5
Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective.儿童急性白血病干细胞移植后的维持治疗：来自一家巴西机构的见解及拉丁美洲视角
Front Oncol. 2025 Mar 5;15:1540158. doi: 10.3389/fonc.2025.1540158. eCollection 2025.
6
A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer.磷脂酰肌醇3-激酶驱动的癌症的代谢合成致死性。
Nat Commun. 2025 Mar 4;16(1):2191. doi: 10.1038/s41467-025-57225-7.
7
Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia.维奈托克与阿扎胞苷联合高三尖杉酯碱、阿糖胞苷和阿柔比星用于复发/难治性T细胞急性淋巴细胞白血病的挽救治疗。
Int J Hematol. 2025 Apr;121(4):547-552. doi: 10.1007/s12185-025-03915-3. Epub 2025 Jan 23.
8
A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient.达雷妥尤单抗、维奈克拉、阿扎胞苷和地塞米松联合治疗使一名经过大量前期治疗且化疗难治的早期T前体急性淋巴细胞白血病/淋巴瘤患者获得完全缓解。
Ann Hematol. 2025 Jan;104(1):829-833. doi: 10.1007/s00277-024-06118-8. Epub 2025 Jan 23.
9
[Ruxolitinib combined with venetoclax and azacitidine in the treatment of refractory T-ALL patients with JAK1, JAK3, and STAT5B gene mutations: a case report and literature review].鲁索替尼联合维奈克拉和阿扎胞苷治疗伴有JAK1、JAK3和STAT5B基因突变的难治性T细胞急性淋巴细胞白血病患者：病例报告及文献综述
Zhonghua Xue Ye Xue Za Zhi. 2024 Sep 14;45(9):872-875. doi: 10.3760/cma.j.cn121090-20240412-00138.
10
[Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia].维奈托克联合多药化疗治疗15例复发或难治性早期T细胞前体急性淋巴细胞白血病的临床疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2023 Aug 14;44(8):649-653. doi: 10.3760/cma.j.issn.0253-2727.2023.08.006.